Vasudev Kantae

Vasudev Kantae

Auto-generated profile, based on publicly available information

Vasudev Kantae

Mechanistic and Structural Biology, Discovery Sciences, R&D

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2017 in Science
Verified
Journal Article
Closed access
PDF file
AEAnnelot C. M. van Esbroeck
Annelot C. M. van Esbroeck
AJAntonius P. A. Janssen
Antonius P. A. Janssen
ACArmand B. Cognetta
Armand B. Cognetta
DODaisuke Ogasawara
Daisuke Ogasawara
GSGuy Shpak
Guy Shpak
MSMario van der Stelt
Mario van der Stelt
A clue to a drug's neurotoxicity?: The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered brain damage. As an initial step in investigating whether inhibition of off-target proteins by BIA 10-2474 might contribute to its clinical neurotoxicity, van Esbroeck et al. used activity-based proteomic assays to identify proteins targeted by the drug. Studying human cells and brain samples from subjects not associated with the trial, they found that BIA 10-2474 targeted several different lipases in addition to FAAH. It also substantially altered lipid metabolism in cultured neurons. Science , this issue p. 1084

19 December 2016 in Metabolomics
Verified
Journal Article
Open access
PDF file
VKVasudev Kantae
Vasudev Kantae
EKElke H. J. Krekels
Elke H. J. Krekels
MEMichiel J. Van Esdonk
Michiel J. Van Esdonk
PLPeter Lindenburg
Peter Lindenburg
AHAmy C. Harms
Amy C. Harms
THThomas Hankemeier
Thomas Hankemeier
Personalized medicine, in modern drug therapy, aims at a tailored drug treatment accounting for inter-individual variations in drug pharmacology to treat individuals effectively and safely. The inter-individual variability in drug response upon drug administration is caused by the interplay between drug pharmacology and the patients’ (patho)physiological status. Individual variations in (patho)physiological status may result from genetic polymorphisms, environmental factors (including current/past treatments), demographic characteristics, and disease related factors. Identification and quantification of predictors of inter-individual variability in drug pharmacology is necessary to achieve personalized medicine. Here, we highlight the potential of pharmacometabolomics in prospectively informing on the inter-individual differences in drug pharmacology, including both pharmacokinetic (PK) and pharmacodynamic (PD) processes, and thereby guiding drug selection and drug dosing. This review focusses on the pharmacometabolomics studies that have additional value on top of the conventional covariates in predicting drug PK. Additionally, employing pharmacometabolomics to predict drug PD is highlighted, and we suggest not only considering the endogenous metabolites as static variables but to include also drug dose and temporal changes in drug concentration in these studies. Although there are many endogenous metabolite biomarkers identified to predict PK and more often to predict PD, validation of these biomarkers in terms of specificity, sensitivity, reproducibility and clinical relevance is highly important. Furthermore, the application of these identified biomarkers in routine clinical practice deserves notable attention to truly personalize drug treatment in the near future.

15 September 2016 in Zebrafish
Verified
Journal Article
Open access
VKVasudev Kantae
Vasudev Kantae
EKElke H.J. Krekels
Elke H.J. Krekels
AOAnita Ordas
Anita Ordas
OGOskar Gonzal
Oskar Gonzal
Rob van WijkRob van Wijk
Rob van Wijk
THThomas Hankemeier
Thomas Hankemeier
Zebrafish larvae ( Danio rerio ) are increasingly used to translate findings regarding drug efficacy and safety from in vitro -based assays to vertebrate species, including humans. However, the limited understanding of drug exposure in this species hampers its implementation in translational research. Using paracetamol as a paradigm compound, we present a novel method to characterize pharmacokinetic processes in zebrafish larvae, by combining sensitive bioanalytical methods and nonlinear mixed effects modeling. The developed method allowed quantification of paracetamol and its two major metabolites, paracetamol-sulfate and paracetamol-glucuronide in pooled samples of five lysed zebrafish larvae of 3 days post-fertilization. Paracetamol drug uptake was quantified to be 0.289 pmole/min and paracetamol clearance was quantified to be 1.7% of the total value of the larvae. With an average volume determined to be 0.290 μL, this yields an absolute clearance of 2.96 × 10 7 L/h, which scales reasonably well with clearance rates in higher vertebrates. The developed methodology will improve the success rate of drug screens in zebrafish larvae and the translation potential of findings, by allowing the establishment of accurate exposure profiles and thereby also the establishment of concentration–effect relationships.

17 June 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MBMarc P. Baggelaar
Marc P. Baggelaar
PCPascal J. P. Chameau
Pascal J. P. Chameau
VKVasudev Kantae
Vasudev Kantae
JHJessica Hummel
Jessica Hummel
KHKu-Lung Hsu
Ku-Lung Hsu
MSMario van der Stelt
Mario van der Stelt

1 March 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
VKVasudev Kantae
Vasudev Kantae
SOShinji Ogino
Shinji Ogino
MNMarek Noga
Marek Noga
AHAmy C. Harms
Amy C. Harms
RDRobin M. van Dongen
Robin M. van Dongen
THThomas Hankemeier
Thomas Hankemeier
Endocannabinoids, a class of lipid messengers, have emerged as crucial regulators of synaptic communication in the central nervous system (CNS). Dysregulation of these compounds has been implicated in many brain disorders. Although some studies have identified and quantified a limited number of target compounds, a method that provides comprehensive quantitative information on endocannabinoids and related N-acylethanolamines (NAEs) in CSF is currently lacking as measurements are challenging due to low concentrations under normal physiological conditions. Here we developed and validated a high-throughput nano liquid chromatography-electrospray ionization mass spectrometry (nano LC-ESI-MS/MS) platform for the simultaneous quantification of endocannabinoids (anandamide (AEA), 2-arachidonoyl glycerol (2-AG)), ten related NAEs and eight additional putatively annotated NAEs in human CSF. Requiring only 200 μL of CSF our method has limits of detection from 0.28 to 61.2 pM with precisions of RSD <15% for most compounds. We applied our method to CSF from 45 healthy humans and demonstrated potential age and gender effects on concentrations of endocannabinoids and NAEs. Notably, our results show that docosahexaenoyl ethanolamide (DHEA) concentrations increase with age in males. Our method may offer new opportunities to gain insight into regulatory functions of endocannabinoids in the context of (ab)normal brain function.

1 October 2019 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
Rob van WijkRob van Wijk
Rob van Wijk
EKElke H.J. Krekels
Elke H.J. Krekels
VKVasudev Kantae
Vasudev Kantae
AOAnita Ordas
Anita Ordas
TKThijs Kreling
Thijs Kreling
PGPiet H. van der Graaf
Piet H. van der Graaf
Zebrafish larvae are increasingly used for pharmacological research, but internal drug exposure is often not measured. Understanding pharmacokinetics is necessary for reliable translation of pharmacological results to higher vertebrates, including humans. Quantification of drug clearance and distribution requires measurements of blood concentrations. Additionally, measuring drug metabolites is of importance to understand clearance in this model organism mechanistically. We therefore mechanistically studied and quantified pharmacokinetics in zebrafish larvae, and compared this to higher vertebrates, using paracetamol (acetaminophen) as a paradigm compound. A method was developed to sample blood from zebrafish larvae 5 days post fertilization. Blood concentrations of paracetamol and its major metabolites, paracetamol-glucuronide and paracetamol-sulfate, were measured. Blood concentration data were combined with measured amounts in larval homogenates and excreted amounts and simultaneously analyzed through nonlinear mixed-effects modeling, quantifying absolute clearance and distribution volume. Blood sampling from zebrafish larvae was most successful from the posterior cardinal vein, with a median volume (interquartile range) of 1.12 nl (0.676-1.66 nl) per blood sample. Samples were pooled (n = 15-35) to reach measurable levels. Paracetamol blood concentrations at steady state were only 10% of the external paracetamol concentration. Paracetamol-sulfate was the major metabolite, and its formation was quantified using a time-dependent metabolic formation rate. Absolute clearance and distribution volume correlated well with reported values in higher vertebrates, including humans. Based on blood concentrations and advanced data analysis, the mechanistic and quantitative understanding of paracetamol pharmacokinetics in zebrafish larvae has been established. This will improve the translational value of this vertebrate model organism in drug discovery and development. SIGNIFICANCE STATEMENT: In early phases of drug development, new compounds are increasingly screened in zebrafish larvae, but the internal drug exposure is often not taken into consideration. We developed innovative experimental and computational methods, including a blood-sampling technique, to measure the paradigm drug paracetamol (acetaminophen) and its major metabolites and quantify pharmacokinetics (absorption, distribution, elimination) in zebrafish larvae of 5 days post fertilization with a total volume of only 300 nl. These parameter values were scaled to higher vertebrates, including humans.